Precision Medicine

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

This year's Shaw Prize honors scientists who turned a deadly leukemia into a curable disease and unraveled the secrets of stellar explosions.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.

A breakthrough 'pap smear for the pancreas' that detects early cancer has secured major funding, offering new hope against one of the deadliest diseases.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Neema Hospitality's 'Hotels for a Cure' campaign, driven by a family's battle with Parkinson's, turns summer travel into vital research support.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

A new telehealth platform offers prescription-only CBD, navigating a major regulatory shift that will reshape the entire cannabis industry. Here's what's next.

By partnering with BioBrasil to produce key diagnostic probes locally, Aliko Scientific is not just entering a market; it's rewriting the rules of play.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.